A Cross-Sectional Seroepidemiological Study on Varicella Zoster Virus in Zhejiang, China
Vaccines · 21.08.2026 · 14 (8) · 722
DOI: 10.3390/vaccines14080722 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Vaccines, online erschienen am 21.08.2026. Verfasst von Yingying Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunization Program, Hangzhou Center for Disease Control and Prevention (Hangzhou Health Supervision Institution), Hangzhou 310021, Ch…. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Disease Prevention and Control Innovation Team of Zhejiang Province.
Abstract (Originalsprache)
Objectives
This study aimed to investigate the levels of varicella antibodies in Zhejiang, China, after a decade of implementing the two-dose varicella vaccine (VarV) strategy.
Methods
Healthy participants aged 1 to 69 years from Zhejiang, China, were recruited from January to April 2024 using multistage stratified random sampling, and varicella zoster virus (VZV) IgG antibodies were detected by ELISA. We assessed the seroprevalence and geometric mean concentration (GMC) of VZV IgG and analyzed related factors using Logistic and linear regression models.
Results
A total of 807 participants were included in the study. The overall seropositivity rate for VZV IgG in the healthy population was 73.08% (95%CI: 69.87–76.11), with a corresponding GMC of 200.97 mIU/mL (95%CI: 182.75 mIU/mL–221.01 mIU/mL). Multivariate analysis identified age group, VarV immunization history, and history of varicella disease as factors significantly associated with both VZV IgG seropositivity and GMC levels (p < 0.05). The seropositivity rate for VZV IgG in children aged 1–14 years was 42.67% (95%CI: 36.22–49.31), with a corresponding GMC of 82.10 mIU/mL (95%CI: 69.14 mIU/mL–97.48 mIU/mL). Furthermore, a significant decline in both seropositivity and GMC was observed over time following vaccination among vaccinated children aged 1–14 years (p < 0.05).
Conclusions
Two-dose VarV vaccination may be considered for inclusion in the national immunization program.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunization Program, Hangzhou Center for Disease Control and Prevention (Hangzhou Health Supervision Institution), Hangzhou 310021, China.
- Department of Immunization Program, Quzhou Center for Disease Control and Prevention (Quzhou Health Supervision Institution), Quzhou 324000, China.
- Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China.
Förderung
- Disease Prevention and Control Innovation Team of Zhejiang Province
Zitieren
APA
Yang, Y., Liu, Y., Zheng, C., Zhu, Y., Chen, F., Ding, L., Hu, Y., Qi, X., & Zhou, Y. (2026). A Cross-Sectional Seroepidemiological Study on Varicella Zoster Virus in Zhejiang, China. Vaccines, 14(8), 722. https://doi.org/10.3390/vaccines14080722
Vancouver
Yang Y, Liu Y, Zheng C, Zhu Y, Chen F, Ding L, et al. A Cross-Sectional Seroepidemiological Study on Varicella Zoster Virus in Zhejiang, China. Vaccines. 2026;14(8):722. doi:10.3390/vaccines14080722
BibTeX
@article{Yang2026,
author = {Yang, Yingying and Liu, Yan and Zheng, Canjie and Zhu, Yao and Chen, Fuxing and Ding, Linling and Hu, Yu and Qi, Xiaohua and Zhou, Yang},
title = {A Cross-Sectional Seroepidemiological Study on Varicella Zoster Virus in Zhejiang, China},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {8},
pages = {722},
doi = {10.3390/vaccines14080722}
}
EUVIMED